ERBB2 and breast carcinoma: Trastuzumab was a humanized monoclonal antibody directed against the HER2/neu oncoprotein and has the ability to inhibit tumor growth in breast cancer patients overexpressing HER2.26 The mean survival of 48 treated patients with trastuzumab and 85 patients without it were 27.8 and 20.8 months.